ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

2.20
0.02 (0.92%)
Last Updated: 08:44:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.02 0.92% 2.20 2.11 2.25 2.20 2.20 2.20 424,396 08:44:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.91 7.27M

Immupharma PLC Grant of Options (8456K)

12/07/2017 11:00am

UK Regulatory


Immupharma (LSE:IMM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Immupharma Charts.

TIDMIMM

RNS Number : 8456K

Immupharma PLC

12 July 2017

12 July 2017

Grant of Options

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,400,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors representing 1.06% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The exercise price for these options is 56.75p pence being the closing middle market share price on 11 July 2017. The options will vest after three years and are exercisable between three and ten years from the date of grant.

The amount of options granted to non-executive Directors are summarised in the following table:

 
     Director       Ordinary Shares 
                      under Option 
-----------------  ---------------- 
   Tim McCarthy        1,000,000 
-----------------  ---------------- 
 Franco di Muzio        200,000 
-----------------  ---------------- 
  Stephane Mery         200,000 
-----------------  ---------------- 
 

Following this grant of all options on the above date, the total number of share options outstanding will be 8,233,850 representing 6.2% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

 
     Director          Number of      % of issued share 
                     Ordinary Shares       capital 
                                       at 11 July 2017 
-----------------  -----------------  ----------------- 
   Tim McCarthy          38,462             0.03% 
-----------------  -----------------  ----------------- 
 Franco di Muzio         99,412             0.08% 
-----------------  -----------------  ----------------- 
  Stephane Mery          21,490             0.02% 
-----------------  -----------------  ----------------- 
 

Following the grant of the options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

 
   Director        Number of    Exercise Price  Expiry Date 
                    Ordinary 
                  Shares under 
                     option 
--------------  --------------  --------------  ----------- 
 Tim McCarthy       500,000         43.88p      02.06.2026 
                   1,000,000        56.75p       12.07.2027 
--------------  --------------  --------------  ----------- 
   Franco di        100,000         76.80p      31.07.2017 
     Muzio 
                    100,000         86.50p       04.02.2019 
                    100,000         43.88p       02.06.2026 
                    200,000         56.75p       12.07.2027 
--------------  --------------  --------------  ----------- 
 Stephane Mery      100,000         43.88p      02.06.2026 
                    200,000         56.75p       12.07.2027 
--------------  --------------  --------------  ----------- 
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends

 
 For further information please contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    Patrick Claridge, David Hignell, 
    Jamie Spotswood, Corporate Finance    +44 (0)20 3861 
    Rob Rees, Corporate Broking                6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHRTMLTMBABMMR

(END) Dow Jones Newswires

July 12, 2017 06:00 ET (10:00 GMT)

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Your Recent History

Delayed Upgrade Clock